← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
26	26 AdaptHealth AHCO $834M	239	-3	-1%	$1.47B
27	27 Wave Life Sciences WVE $609M	239	+7	+3%	$1.06B
28	28 Dr. Reddy's Laboratories RDY $10.6B	238	-11	-4%	$1.82B
29	29 Herbalife HLF $1.49B	235	-18	-7%	$1.37B
30	30 Utz Brands UTZ $1.27B	235	+9	+4%	$584M
31	31 Fresenius Medical Care FMS $11.5B	234	+14	+6%	$960M
32	32 Tootsie Roll Industries TR $2.87B	232	+10	+5%	$509M
33	33 Opko Health OPK $1.02B	222	-14	-6%	$303M
34	34 Amphastar Pharmaceuticals AMPH $1.11B	211	-4	-2%	$572M
35	35 Altimmune ALT $449M	210	+37	+21%	$456M
36	36 Amylyx Pharmaceuticals AMLX $3.39B	206	+35	+20%	$2.07B
37	37 Structure Therapeutics GPCR $1.56B	191	-5	-3%	$3.62B
38	38 Krispy Kreme DNUT $529M	181	+5	+3%	$290M
39	39 MBX Biosciences MBX $2.35B	172	+15	+10%	$3.06B
40	40 Septerna Inc SEPN $1.7B	153	+29	+23%	$1.58B
41	41 BioAge Labs BIOA $249M	150	+6	+4%	$925M
42	42 Lexicon Pharmaceuticals LXRX $712M	149	+13	+10%	$875M
43	43 Accendra Health ACH $24.1M	139	-4	-3%	$213M
44	44 Stevanato STVN $5.27B	125	-10	-7%	$809M
45	45 Sagimet Biosciences SGMT $535M	122	+34	+39%	$394M
46	46 LifeMD LFMD $114M	116	+14	+14%	$89.3M
47	47 Medifast MED $132M	112	0	0%	$87.7M
48	48 Corbus Pharmaceuticals CRBP $85.3M	107	-1	-0.9%	$129M
49	49 AirSculpt Technologies AIRS $102M	102	+13	+15%	$205M
50	50 Kailera Therapeutics KLRA $1.39B	100	+100	–	$2.57B